The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment)
|出版日||ページ情報||英文 230 Pages
|院内感染管理市場(殺菌・消毒・検査・治療) The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment)|
|出版日: 2013年08月09日||ページ情報: 英文 230 Pages||
Given the cost of hospital-acquired and healthcare-associated infections (HAIs), demand has increased for solutions that can help the healthcare industry reduce infections and the costs associated with them. The U.S. Centers for Disease Control and Prevention (CDC) estimates that around 1 in 20 or 5% of hospitalized patients will contract an HAI. Worldwide, the rate of nosocomial infections is between 3.5% and 12% of admissions in developed regions. This has created a market opportunity for companies that can test for, treat and help prevent these infections. This opportunity is detailed in Kalorama Information's report, The Market for Hospital-Acquired Infection Control (Sterilization, Cleaning, Testing, Treatment)
This report focuses on preventing, testing and treating infections in the healthcare environment. The major consideration is given to bacterial nosocomial infections because a) they are the most frequent type of infections spread in the health care delivery setting, and b) the practical aspects of diagnosis and therapy are more meaningful based on a combination of medical and financial considerations.
The report will provide a market analysis for each of the three areas:
The infection control market is a stable one for companies involved in these areas. As long as there are infections there will always be a need for controlling these infections. It is a fact that diseases evolve and that new approaches to preventing, diagnosing and treating will be required for the long-term.
Market analysis in this report considers primarily the epidemiological considerations and the size patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis.
Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic and therapeutic products). In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital and primary care environment in order to construct a picture of the infection prevention, testing and treatment needs.
In looking at infections in the health environment, we consider the diagnostic and therapeutic technologies that are currently available and attempt to project trends for preventing, detecting and treating these infections. To some extent, we are limited by the activity of the industries associated with the activities mentioned above for these infections. For the most part, these activities are limited and the advanced technologies seen in other areas of medical application are not necessarily present in terms of microbiology.
The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, reimbursement specialists, research scientists, business development managers and marketing managers.
The majority of competitive participation for Hospital-Acquired Infection control and is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America.
Companies included in this report are: